A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2
A Potently Neutralizing Antibody Protects Mice against SARS-CoV-2 Infection | The Journal of Immunology
Broadening of Neutralization Activity to Directly Block a Dominant Antibody-Driven SARS-Coronavirus Evolution Pathway
Three epitope-distinct human antibodies from RenMab mice neutralize SARS-CoV-2 and cooperatively minimize the escape of mutants | Cell Discovery
Ultrapotent SARS-CoV-2 neutralizing antibodies with protective efficacy against newly emerged mutational variants | bioRxiv
Structural Bases of Coronavirus Attachment to Host Aminopeptidase N and Its Inhibition by Neutralizing Antibodies
Generation and characterization of human monoclonal neutralizing antibodies with distinct binding and sequence features against SARS coronavirus using XenoMouse® - ScienceDirect
Identification of human neutralizing antibodies against MERS-CoV and their role in virus adaptive evolution | PNAS
Therapy with a Severe Acute Respiratory Syndrome–Associated Coronavirus–Neutralizing Human Monoclonal Antibody Reduces Disease Severity and Viral Burden in Golden Syrian Hamsters | The Journal of Infectious Diseases | Oxford Academic
Screening of potent neutralizing antibodies against SARS-CoV-2 using convalescent patients-derived phage-display libraries | Cell Discovery
A glycan cluster on the SARS-CoV-2 spike ectodomain is recognized by Fab-dimerized glycan-reactive antibodies | bioRxiv
Human monoclonal antibodies block the binding of SARS-CoV-2 spike protein to angiotensin converting enzyme 2 receptor | Cellular & Molecular Immunology
A human monoclonal antibody blocking SARS-CoV-2 infection | Nature Communications
Human-IgG-Neutralizing Monoclonal Antibodies Block the SARS-CoV-2 Infection - ScienceDirect
Cross-reactive coronavirus antibodies with diverse epitope specificities and Fc effector functions - ScienceDirect
A humanized neutralizing antibody against MERS-CoV targeting the receptor-binding domain of the spike protein | Cell Research
A dominant antigenic epitope on SARS-CoV spike protein identified by an avian single-chain variable fragment (scFv)-expressing phage - ScienceDirect
Potent neutralization of SARS-CoV-2 variants of concern by an antibody with a unique genetic signature and structural mode of spike recognition | bioRxiv
A monoclonal antibody against staphylococcal enterotoxin B superantigen inhibits SARS-CoV-2 entry in vitro | bioRxiv
PLOS ONE: Page Not Found
Structural definition of a neutralization epitope on the N-terminal domain of MERS-CoV spike glycoprotein | Nature Communications
Structural Basis of Neutralization by a Human Anti-severe Acute Respiratory Syndrome Spike Protein Antibody, 80R* - Journal of Biological Chemistry
Paired heavy and light chain signatures contribute to potent SARS-CoV-2 neutralization in public antibody responses | bioRxiv
Antibodies with potent and broad neutralizing activity against antigenically diverse and highly transmissible SARS-CoV-2 variants | bioRxiv
Ultrapotent antibodies against diverse and highly transmissible SARS-CoV-2 variants
Naive human B cells can neutralize SARS-CoV-2 through recognition of its receptor binding domain | bioRxiv
Rapid identification of a human antibody with high prophylactic and therapeutic efficacy in three animal models of SARS-CoV-2 infection | PNAS
Ultrapotent Human Neutralizing Antibody Repertoires Against Middle East Respiratory Syndrome Coronavirus From a Recovered Patient | The Journal of Infectious Diseases | Oxford Academic
A rapid and efficient screening system for neutralizing antibodies and its application for the discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD | bioRxiv
Neutralizing antibodies targeting the SARS-CoV-2 receptor binding domain isolated from a naïve human antibody library | bioRxiv
Production of an Anti-Severe Acute Respiratory Syndrome (SARS) Coronavirus Human Monoclonal Antibody Fab Fragment by Using a Combinatorial Immunoglobulin Gene Library Derived from Patients Who Recovered from SARS | Clinical and Vaccine Immunology
Extremely potent human monoclonal antibodies from COVID-19 convalescent patients - ScienceDirect
A human SARS-CoV neutralizing antibody against epitope on S2 protein - ScienceDirect
Mouse Antibodies with Activity Against the SARS-CoV-2 D614G and B.1.351 Variants | bioRxiv
A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2
Structural basis for broad coronavirus neutralization | Nature Structural & Molecular Biology
404
Structures of potent and convergent neutralizing antibodies bound to the SARS-CoV-2 spike unveil a unique epitope responsible for exceptional potency | bioRxiv
Potent Neutralizing Antibodies against SARS-CoV-2 Identified by High-Throughput Single-Cell Sequencing of Convalescent Patients’ B Cells - ScienceDirect
Structures of SARS-CoV-2 B.1.351 neutralizing antibodies provide insights into cocktail design against concerning variants | Cell Research
B cell genomics behind cross-neutralization of SARS-CoV-2 variants and SARS-CoV - ScienceDirect
Therapeutic antibodies, targeting the SARS-CoV-2 spike N-terminal domain, protect lethally infected K18-hACE2 mice - ScienceDirect
Convergent antibody responses to SARS-CoV-2 in convalescent individuals | Nature
Evolution of antibody immunity to SARS-CoV-2 | Nature
Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection | Nature
Memory B cell repertoire for recognition of evolving SARS-CoV-2 spike - ScienceDirect
Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals | bioRxiv
Molecular basis for a germline-biased neutralizing antibody response to SARS-CoV-2 | bioRxiv
mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants | Nature
Nature - Not Found
Structure and function analysis of a potent human neutralizing antibody CA521FALA against SARS-CoV-2 | Communications Biology
Cross-reactive serum and memory B-cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection | Nature Communications
Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model
Importance of Neutralizing Monoclonal Antibodies Targeting Multiple Antigenic Sites on the Middle East Respiratory Syndrome Coronavirus Spike Glycoprotein To Avoid Neutralization Escape | Journal of Virology
Prevalent, protective, and convergent IgG recognition of SARS-CoV-2 non-RBD spike epitopes
Redirecting
Sequence signatures of two IGHV3-53/3-66 public clonotypes to SARS-CoV-2 receptor binding domain | bioRxiv
Convergent antibody responses to the SARS-CoV-2 spike protein in convalescent and vaccinated individuals | bioRxiv
Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein | Nature Medicine
Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability
The antigenic anatomy of SARS-CoV-2 receptor binding domain - ScienceDirect
Antibody evasion by the P.1 strain of SARS-CoV-2 - ScienceDirect
Molecular and Biological Characterization of Human Monoclonal Antibodies Binding to the Spike and Nucleocapsid Proteins of Severe Acute Respiratory Syndrome Coronavirus | Journal of Virology
Full article: Potent SARS-CoV-2 binding and neutralization through maturation of iconic SARS-CoV-1 antibodies
Human Monoclonal Antibody Combination against SARS Coronavirus: Synergy and Coverage of Escape Mutants
SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies | bioRxiv
A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model | bioRxiv
Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual | bioRxiv
Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects | bioRxiv
Ultrapotent bispecific antibodies neutralize emerging SARS-CoV-2 variants | bioRxiv
Evaluation of candidate vaccine approaches for MERS-CoV | Nature Communications
Accelerated Antibody Discovery Targeting the SARS-CoV-2 Spike Protein for COVID-19 Therapeutic Potential | bioRxiv
Fragment-based computational design of antibodies targeting structured epitopes | bioRxiv
The functions of SARS-CoV-2 neutralizing and infection-enhancing antibodies in vitro and in mice and nonhuman primates | bioRxiv
Discovery of nanobodies against SARS-CoV-2 and an uncommon neutralizing mechanism | bioRxiv
Broadening a SARS-CoV-1 neutralizing antibody for potent SARS-CoV-2 neutralization through directed evolution | bioRxiv
Single-cell sequencing of plasma cells from COVID-19 patients reveals highly expanded clonal lineages produce specific and neutralizing antibodies to SARS-CoV-2 | bioRxiv
Structural basis for the neutralization of SARS-CoV-2 by an antibody from a convalescent patient | bioRxiv
Molecular characterization of a panel of murine monoclonal antibodies specific for the SARS-coronavirus - ScienceDirect
Structural Insights into Immune Recognition of the Severe Acute Respiratory Syndrome Coronavirus S Protein Receptor Binding Domain - ScienceDirect
Multivalency transforms SARS-CoV-2 antibodies into ultrapotent neutralizers | Nature Communications
Potent SARS-CoV-2 neutralizing antibodies directed against spike N-terminal domain target a single supersite - ScienceDirect
Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike | Nature
Structure-based development of human antibody cocktails against SARS-CoV-2 | Cell Research
Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen | PNAS
A potent neutralizing nanobody against SARS‐CoV‐2 with inhaled delivery potential - Gai - 2021 - MedComm - Wiley Online Library
Synthetic repertoires derived from convalescent COVID-19 patients enable discovery of SARS-CoV-2 neutralizing antibodies and a novel quaternary binding modality | bioRxiv
Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic antibody | bioRxiv
Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2 | Nature Structural & Molecular Biology
Figure 2 from 645 Duan.qxp | Semantic Scholar
Double lock of a potent human therapeutic monoclonal antibody against SARS-CoV-2 | National Science Review | Oxford Academic
An affinity-enhanced, broadly neutralizing heavy chain–only antibody protects against SARS-CoV-2 infection in animal models
A potent SARS-CoV-2 neutralising nanobody shows therapeutic efficacy in the Syrian golden hamster model of COVID-19 | Research Square
Identification of an anti–SARS–CoV-2 receptor-binding domain–directed human monoclonal antibody from a naïve semisynthetic library - Journal of Biological Chemistry
Deep mining of early antibody response in COVID-19 patients yields potent neutralisers and reveals high level of convergence | bioRxiv
Directed evolution of potent neutralizing nanobodies against SARS-CoV-2 using CDR-swapping mutagenesis - ScienceDirect
Cross-reactivity of antibody against SARS-coronavirus nucleocapsid protein with IL-11 - ScienceDirect
Prophylactic and postexposure efficacy of a potent human monoclonal antibody against MERS coronavirus | PNAS
Potent synthetic nanobodies against SARS-CoV-2 and molecular basis for neutralization | bioRxiv
Chicken single-chain variable fragments against the SARS-CoV spike protein - ScienceDirect
LY-CoV1404 potently neutralizes SARS-CoV-2 variants | bioRxiv
LY-CoV555, a rapidly isolated potent neutralizing antibody, provides protection in a non-human primate model of SARS-CoV-2 infection | bioRxiv
Human Neutralizing Fab Molecules against Severe Acute Respiratory Syndrome Coronavirus Generated by Phage Display | Clinical and Vaccine Immunology
Junctional and allele-specific residues are critical for MERS-CoV neutralization by an exceptionally potent germline-like antibody | Nature Communications
Exceptionally Potent Neutralization of Middle East Respiratory Syndrome Coronavirus by Human Monoclonal Antibodies | Journal of Virology
Characterization of germline antibody libraries from human umbilical cord blood and selection of monoclonal antibodies to viral envelope glycoproteins: Implications for mechanisms of immune evasion and design of vaccine immunogens - ScienceDirect
Structure of Severe Acute Respiratory Syndrome Coronavirus Receptor-binding Domain Complexed with Neutralizing Antibody* - Journal of Biological Chemistry
Potent neutralizing RBD‐specific antibody cocktail against SARS‐CoV‐2 and its mutant - Jia - 2021 - MedComm - Wiley Online Library
Broad neutralization of SARS-related viruses by human monoclonal antibodies
Rapid development of neutralizing and diagnostic SARS-COV-2 mouse monoclonal antibodies | Scientific Reports
Development of SARS-CoV-2 Nucleocapsid Specific Monoclonal Antibodies | bioRxiv
Human Neutralizing Monoclonal Antibody Inhibition of Middle East Respiratory Syndrome Coronavirus Replication in the Common Marmoset | The Journal of Infectious Diseases | Oxford Academic
A panel of human neutralizing mAbs targeting SARS-CoV-2 spike at multiple epitopes | Nature Communications
Potent Neutralization of MERS-CoV by Human Neutralizing Monoclonal Antibodies to the Viral Spike Glycoprotein
Human single-chain antibodies neutralize SARS-CoV-2 variants by engaging an essential epitope of the spike: a new weapon against COVID-19 | bioRxiv
Rapid Identification of Neutralizing Antibodies against SARS-CoV-2 Variants by mRNA Display | bioRxiv
Isolation and identification of an scFv antibody against nucleocapsid protein of SARS-CoV - ScienceDirect
The development of Nanosota-1 as anti-SARS-CoV-2 nanobody drug candidates | eLife
An ultrapotent synthetic nanobody neutralizes SARS-CoV-2 by stabilizing inactive Spike
Versatile and multivalent nanobodies efficiently neutralize SARS-CoV-2
A potent neutralizing nanobody against SARS-CoV-2 with inhaled delivery potential | bioRxiv
Characterization of protease activity of Nsp3 from SARS-CoV-2 and its in vitro inhibition by nanobodies | bioRxiv
Identification of potent human neutralizing antibodies against SARS-CoV-2 implications for development of therapeutics and prophylactics | Nature Communications
High affinity nanobodies block SARS-CoV-2 spike receptor binding domain interaction with human angiotensin converting enzyme | Scientific Reports
NeutrobodyPlex—monitoring SARS‐CoV‐2 neutralizing immune responses using nanobodies | EMBO reports
Single-Domain Antibodies for the Detection of SARS-CoV-2 Nucleocapsid Protein | Analytical Chemistry
Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant - ScienceDirect
SARS-CoV-2 can recruit a heme metabolite to evade antibody immunity
Rational development of a human antibody cocktail that deploys multiple functions to confer Pan-SARS-CoVs protection | Cell Research
Potent and protective IGHV3-53/3-66 public antibodies and their shared escape mutant on the spike of SARS-CoV-2 | Nature Communications
Structural basis for bivalent binding and inhibition of SARS-CoV-2 infection by human potent neutralizing antibodies | bioRxiv
Human neutralizing antibodies elicited by SARS-CoV-2 infection | Nature
Broad betacoronavirus neutralization by a stem helix–specific human antibody
A SARS-CoV-2 neutralizing antibody with extensive Spike binding coverage and modified for optimal therapeutic outcomes | Nature Communications
Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domain - ScienceDirect
Glycan reactive anti-HIV-1 antibodies bind the SARS-CoV-2 spike protein but do not block viral entry | bioRxiv
Structural basis for SARS-CoV-2 neutralizing antibodies with novel binding epitopes
Structure of a germline-like human antibody defines a neutralizing epitope on the SARS-CoV-2 spike NTD | bioRxiv
Effect of SARS-CoV-2 B.1.1.7 mutations on spike protein structure and function | Nature Structural & Molecular Biology
Development of Multivalent Nanobodies Blocking SARS CoV 2 Infection by Targeting RBD of Spike Protein | Research Square
Rapid generation of potent antibodies by autonomous hypermutation in yeast | bioRxiv
Neutralization of SARS‐CoV‐2 by highly potent, hyperthermostable, and mutation‐tolerant nanobodies | The EMBO Journal
Pre- and postexposure efficacy of fully human antibodies against Spike protein in a novel humanized mouse model of MERS-CoV infection | PNAS
Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail
Potent SARS-CoV-2 neutralizing antibodies selected from a human antibody library constructed decades ago | bioRxiv
Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody | Nature
Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms
SARS-CoV-2 immune evasion by the B.1.427/B.1.429 variant of concern
Redirecting
SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape | Nature
Structural basis for broad sarbecovirus neutralization by a human monoclonal antibody | bioRxiv
Broad sarbecovirus neutralization by a human monoclonal antibody | Nature
Identification of single-chain antibody fragments specific against SARS-associated coronavirus from phage-displayed antibody library - ScienceDirect
A potently neutralizing anti-SARS-CoV-2 antibody inhibits variants of concern by binding a highly conserved epitope | bioRxiv
Sybodies targeting the SARS-CoV-2 receptor-binding domain | bioRxiv
| bioRxiv
Selection, biophysical and structural analysis of synthetic nanobodies that effectively neutralize SARS-CoV-2 | Nature Communications
Humanized single domain antibodies neutralize SARS-CoV-2 by targeting the spike receptor binding domain | Nature Communications
Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking | bioRxiv
SARS-CoV-2 neutralizing human recombinant antibodies selected from pre-pandemic healthy donors binding at RBD-ACE2 interface | Nature Communications
Multi-clonal SARS-CoV-2 neutralization by antibodies isolated from severe COVID-19 convalescent donors
A pair of non-competing neutralizing human monoclonal antibodies protecting from disease in a SARS-CoV-2 infection model | bioRxiv
SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses | Nature
An alpaca nanobody neutralizes SARS-CoV-2 by blocking receptor interaction | Nature Communications
Bi-paratopic and multivalent human VH domains neutralize SARS-CoV-2 by targeting distinct epitopes within the ACE2 binding interface of Spike | bioRxiv
Chimeric camel/human heavy-chain antibodies protect against MERS-CoV infection
Structural Basis for Potent Neutralization of Betacoronaviruses by Single-Domain Camelid Antibodies - ScienceDirect
Structure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape
Fast isolation of sub-nanomolar affinity alpaca nanobody against the Spike RBD of SARS-CoV-2 by combining bacterial display and a simple single-step density gradient selection | bioRxiv
Enhanced SARS-CoV-2 neutralization by dimeric IgA
Nanobody cocktails potently neutralize SARS-CoV-2 D614G N501Y variant and protect mice | PNAS
A potent bispecific nanobody protects hACE2 mice against SARS-CoV-2 infection via intranasal administration | bioRxiv
Toolkit for Quickly Generating and Characterizing Molecular Probes Specific for SARS-CoV-2 Nucleocapsid as a Primer for Future Coronavirus Pandemic Preparedness | ACS Synthetic Biology
Enhancement versus neutralization by SARS-CoV-2 antibodies from a convalescent donor associates with distinct epitopes on the RBD - ScienceDirect
Nanobodies from camelid mice and llamas neutralize SARS-CoV-2 variants | Nature
Diverse immunoglobulin gene usage and convergent epitope targeting in neutralizing antibody responses to SARS-CoV-2 - ScienceDirect
